Immix Biopharma, Inc.

(a)The below events occurred within four business days of the filing date of this periodic report and as such, the Company is disclosing the occurrence of the events underItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, below instead of in a stand-alone Current Report on Form 8-K:

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

Effective on November 3, 2025, the Board of Directors of the Company, with the recommendation of the Compensation Committee of the Board of Directors of the Company, agreed to clarify and amend each of the prior outstanding options of the Company granted under the Company’s 2021 Omnibus Equity Incentive Plan, as amended and restated from time to time (the “Plan”) and held by (a) non-management personnel (employees and consultants), so that if such non-management personnel are terminated, other than due to death, disability, or cause, upon the closing of a Change in Control (as defined in the Plan) or within twelve (12) months following such Change in Control, then all unvested options held by the such persons would immediately become fully vested and exercisable on the date of termination and shall terminate and be canceled on the earlier of: (i) the expiration of the term; or (ii) ninety (90) days after such termination date; and (b) non-employee directors and management, such that in the event of a Change in Control, all unvested options held by such non-employee directors or management shall immediately become fully vested and exercisable on the date of such Change in Control.

Such amendments are subject in all cases to the entry by the Company into first amendment to stock option grant notice and option agreements with each option holder, which the Company expects to have completed in the next several days.

*(c) Rule 10b5-1 Trading Plans.*During the quarter ended September 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f))adopted orterminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement”.